Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217709 · ClinicalTrials.gov registry record · Phase 2
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02217709 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 26 participants.
The verdict
NCT02217709, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- DRUG phenelzine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-09-08 |
| Est. Completion | 2020-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02217709
The ClinicalTrials.gov registry entry for NCT02217709 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02217709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02217709 about?
NCT02217709 is a clinical study titled "Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer". This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may hav...
What is the current status of trial NCT02217709?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-09-08. Estimated completion is 2020-06-29.
What interventions are being tested in trial NCT02217709?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), phenelzine sulfate (DRUG).
Who is sponsoring clinical trial NCT02217709?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.